|
Published by: Business Monitor International
Published: Jan. 1, 2007 - 55 Pages
Table of Contents
- Chapter 1 - Executive Summary
- Hungary Pharmaceuticals & Healthcare Industry SWOT
- Hungary Political SWOT
- Hungary Economic SWOT
- Hungary Business Environment SWOT
- Chapter 2 - Business Environment Rankings
- Central & Eastern European Region
- Table: Central & Eastern Europe Pharmaceuticals Business Environment Ranking
- Business Environment Ranking
- Economics - Long-Term Risk
- Politics - Long-Term Risk
- Regulatory Barriers
- Domestic Sector Threat
- Market Growth Potential
- Market Size Ranking
- Chapter 3 - Market Overview
- Table: Leading Pharmaceutical Companies by Ownership
- Chapter 4 - Regulatory Regime
- Healthcare Reforms
- Intellectual Property Regime
- Pricing & Reimbursement Issues
- Epidemiological Trends
- CRO Sector
- Chapter 5 - Industry Forecast Scenario
- Overall Market Forecast
- Table: Drug Market Indicator Forecasts 2004-2010
- Key Growth Factors - Industry
- Table: Health Expenditure Indicator Forecasts 2004-2010
- Key Growth Factors - Macroeconomic
- Table: Nominal And Real GDP
- OTC Market Forecast
- Table: OTC Market Indicator Forecasts 2004-2009
- Prescription Market Forecast
- Table: Prescription Drug Market Forecasts 2004-2010
- Generics & Branded Markets Forecast
- Table: Generics And Branded Market Indicator Forecasts 2004-2010
- Export/Import Forecasts
- Table: Import/Export Market Forecasts 2004-2010
- Key Risks to BMI’s Forecast Scenario
- Chapter 6 - Country Snapshot: Hungary Demographic Data
- Section 1: Population:
- Table: Demographic Indicators (2005)
- Table: Rural/Urban Breakdown
- Section 2: Education & Healthcare
- Table: Education
- Table: Healthcare: Vital Statistics
- Table: Healthcare: Expenditure
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators
- Table: Consumption and Stratification
- Table: Wages per year
- Chapter 7 - Competitive Landscape
- Company Monitor
- Egis Pharmaceuticals (Servier)
- Eli Lilly
- Gedeon Richter
- Krka
- Chapter 8 - BMI Forecast Modelling
- How we generate our industry forecasts
- Technical Process
- Pharmaceuticals Industry
- Sources
- Chapter 9 - Appendix: Regional Demographic Data
- Wages (ave. labour force per annum), US$ PPP
- Population
- Household Spending Per Capita, US$
- Private Consumption Per Capita, US$ PPP
- Market Size, GDP, US$bn
AbstractThe Hungarian pharmaceuticals market is characterised by over-consumption, insufficient insurance fund contributors and an increasingly challenging operating environment for both generic and branded drug companies, according to our newly-published ""Hungary Pharmaceuticals & Healthcare Report"". However, the country has an enviable market size and robust growth is forecast, with the value of the pharmaceutical market expected to reach nearly US$5bn by 2010.
Amid attempts to cut the country's budget deficit ahead of euro adoption in 2011, Hungary announced drastic changes to its healthcare system in September 2006, including new fees to see doctors, patient co-payments and new pharmacy rules. These reforms were criticised by opposition parties and by the general population, but the government pointed out that receiving the highest level of medical care with no cost penalties is not a tenable situation, hence the changes.
Instances of foreign direct investment in Hungary are increasing. GSK Biologicals announced in September 2006 that it is to build a EUR100mn (US$128mn) vaccines production facility in Godollo, outside capital city Budapest. The plant will be one of Europe's most advanced biotechnology facilities, and it will manufacture two vaccine products.
BMI's adjusted Business Environment Rankings for Central & Eastern Europe place Hungary in eighth place, down from its premier position in Q206. The primary reason for this fall is the emergence of countries like Russia and Romania as extremely attractive places for pharmaceutical companies to operate. Nevertheless, Hungary still remains an important destination for multinationals due to its favourable geographical location and transparent operating environment.
The competitive landscape is dominated by two large domestic producers, Egis and Gedeon Richter. Both have recently posted robust financial results; however, the companies reduced their financial forecasts for 2006 as a result of price cuts and new taxes announced by the Prime Minister. Assuming the 4% ""solidarity tax"" on profit before taxation is approved, Gedeon Richter's profit may fall by up US$2.7mn per annum.
Key Benefits of Report
Rely On Our Independent 5-Year Forecasts As A Benchmark
to test other views - a key input for successful budgetary and strategic business planning.
Target Business Opportunities & Risks
through our reviews of latest industry trends, regulatory changes, and major deals, projects and investments
Exploit Latest Competitive Intelligence & Company SWOTS
on your competitors and peers through company rankings by sales, market share and ownership structure - includes multinational and national companies.
Get Full Details About This Report >>
|
